Incidence of grade 4 CRS was 27% in patients with baseline high tumor burden (≥40% tumor blasts in bone marrow) with prophylactic tocilizumab, versus 50% in a prior phase I trial of tisagenlecleucel ...
LYR-220, Lyra’s second product candidate, is a long-acting anti-inflammatory therapy in development for CRS patients with and without polyps who have recurrent symptoms despite prior ethmoid sinus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback